Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938
hospira,-inc-issues-a-voluntary-nationwide-recall-for-4.2%-sodium-bicarbonate-injection,-usp-and-1%-and-2%-lidocaine-hcl-injection,-usp-due-to-the-potential-for-presence-of-glass-particulate-matter Drug Test
  • February 26, 2025

Hospira, Inc. Issues a Voluntary Nationwide Recall for 4.2% Sodium Bicarbonate Injection, USP and 1% and 2% Lidocaine HCl Injection, USP Due to the Potential for Presence of Glass Particulate Matter

Hospira, Inc., a Pfizer company, is voluntarily recalling the lots listed in the table below of 4.2% Sodium Bicarbonate Injection,…
questions-and-answers:-integration-of-fda-facility-evaluation-and-inspection-program-for-human-drugs:-a-concept-of-operations Drug Test
  • February 26, 2025

Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations

Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations
benefits-of-emerging-technology-program-(etp) Drug Test
  • February 26, 2025

Benefits of Emerging Technology Program (ETP)

CDER’s Office of Pharmaceutical Quality created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product…
transcript:-emerging-technology-program Drug Test
  • February 26, 2025

Transcript: Emerging Technology Program

FDA’s Emerging Technology Program is intended to encourage technology for use in product design and pharmaceutical manufacturing
advancing-product-quality Drug Test
  • February 26, 2025

Advancing Product Quality

FDA is engaged in efforts to encourage innovations in manufacturing processes and technology and to foster a quality management system.
advancing-product-quality-for-human-drugs Drug Test
  • February 26, 2025

Advancing Product Quality for Human Drugs

FDA is engaged in efforts to encourage innovations in manufacturing processes and technology and to foster a quality management system.
drug-shortages-|-additional-news-and-information Drug Test
  • February 26, 2025

Drug Shortages | Additional News and Information

Drug Shortages: Additional News and Information
advances-in-fda’s-drug-safety-programs Drug Test
  • February 26, 2025

Advances in FDA’s Drug Safety Programs

Drug Safety is a Key Priority at the Center for Drug Evaluation and Research
oncologic-drugs-advisory-committee-roster Drug Test
  • February 25, 2025

Oncologic Drugs Advisory Committee Roster

ODAC roster, a lists the current members and the current number of vacancies for the committee
fda-drug-safety-communication:-fda-modifies-monitoring-for-neutropenia-associated-with-schizophrenia-medicine-clozapine;-approves-new-shared-rems-program-for-all-clozapine-medicines Drug Test
  • February 25, 2025

FDA Drug Safety Communication: FDA modifies monitoring for neutropenia associated with schizophrenia medicine clozapine; approves new shared REMS program for all clozapine medicines

[09-15-2015] The U.S. Food and Drug Administration (FDA) is making changes to the requirements for monitoring, prescribing, dispensing, and receiving…